/content/mofsl-website-adobe/fragments/open-demat-popup

style

hide-in-desktop

PolyPid Ltd share price today is $4.19, up -4.14%. The stock opened at $4.25 against the previous close of $4.35, with an intraday high of $4.25 and low of $4.19.

style

pb-0

PolyPid Ltd

/content/mofsl-website-adobe/demat-form-fields

style

sticky-block,pt-0

us-stock

style

pt-0

$4.19 -0.0414(-4.14%) PYPD at 13 Mar 2026 02:54 PM Biotechnology

Lowest Today 4.19

Highest Today 4.25

Today’s Open 4.25

Prev. Close 4.35

52 Week High 5.12

52 Week Low 2.30

Day’s Range: Low 4.19 High 4.25

52-Week Range: Low 2.30 High 5.12

PolyPid Ltd Institutional Holdings

PolyPid Ltd Market Status

Strong Buy: 1

Buy: 3

Hold: 0

Sell: 0

Strong Sell: 0

PolyPid Ltd Fundamentals

Market Cap 83.01 M

PB Ratio 7.5651

PE Ratio 0.0

Enterprise Value 72.88 M

Total Assets 22.31 M

Volume 20552

PolyPid Ltd Company Financials

Annual Revenue FY25:null 0.0M, FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M

Annual Profit FY25:null 0.0M, FY23:null 0.0M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M

Annual Net worth FY25:-34169000 -34.2M, FY23:-24076000 -24.1M, FY22:-39525000 -39.5M, FY21:-40713000 -40.7M, FY20:-35324000 -35.3M

Quarterly Revenue Q4/2025:null 0.0M, Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M

Quarterly Profit Q4/2025:null 0.0M, Q3/2025:null 0.0M, Q2/2025:null 0.0M, Q1/2025:null 0.0M, Q3/2024:null 0.0M

Quarterly Net worth Q4/2025:-8473000 -8.5M, Q3/2025:-7451000 -7.5M, Q2/2025:-9977000 -10.0M, Q1/2025:-8268000 -8.3M, Q3/2024:-7760000 -7.8M

About PolyPid Ltd & investment objective

Company Information PolyPid Ltd., a biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The company is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Organisation Biotechnology

Employees 69

Industry Biotechnology

CEO Ms. Dikla Czaczkes Akselbrad

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*